

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

David J. Rog, BMBS; Turo J. Nurmikko, PhD; Tim Friede, PhD; and Carolyn A. Young, MD

Abstract—Background: Central pain in multiple sclerosis (MS) is common and often refractory to treatment. **Methods:** We conducted a single-center, 5-week (1-week run-in, 4-week treatment), randomized, double-blind, placebo-controlled, parallel-group trial in 66 patients with MS and central pain states (59 dysesthetic, seven painful spasms) of a whole-plant cannabis-based medicine (CBM), containing delta-9-tetrahydrocannabinol:cannabidiol (THC:CBD) delivered via an oromucosal spray, as adjunctive analgesic treatment. Each spray delivered 2.7 mg of THC and 2.5 of CBD, and patients could gradually self-titrate to a maximum of 48 sprays in 24 hours. **Results:** Sixty-four patients (97%) completed the trial, 34 received CBM. In week 4, the mean number of daily sprays taken of CBM ($n = 32$) was 9.6 (range 2 to 25, SD = 6.0) and of placebo ($n = 31$) was 19.1 (range 1 to 47, SD = 12.9). Pain and sleep disturbance were recorded daily on an 11-point numerical rating scale. CBM was superior to placebo in reducing the mean intensity of pain (CBM mean change -2.7 , 95% CI: -3.4 to -2.0 , placebo -1.4 , 95% CI: -2.0 to -0.8 , comparison between groups, $p = 0.005$) and sleep disturbance (CBM mean change -2.5 , 95% CI: -3.4 to -1.7 , placebo -0.8 , 95% CI: -1.5 to -0.1 , comparison between groups, $p = 0.003$). CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence. Cognitive side effects were limited to long-term memory storage. **Conclusions:** Cannabis-based medicine is effective in reducing pain and sleep disturbance in patients with multiple sclerosis related central neuropathic pain and is mostly well tolerated.

NEUROLOGY 2005;65:812–819

Central pain, i.e., pain initiated or caused by a primary lesion or dysfunction of the CNS,¹ is estimated to occur in between 17% and 52% of people with multiple sclerosis (MS).² As many as 32% of patients with MS regard pain among their most severe symptoms,³ confirming it as a “frequent, disabling and inadequately managed symptom.”⁴ The most common form of central pain in MS is nonparoxysmal extremity pain, which shows large interindividual variation and may manifest with several, typically dysesthetic, qualities such as burning, aching, pricking, stabbing, or squeezing.² Painful extremity spasms have also been classed as central pain.⁵

In the past decade, cannabinoids and the endocan-

nabinoid system have come under intense scrutiny following the discovery of CB1 and CB2 receptors and development of specific cannabinoid receptor agonist and antagonist ligands.⁶ The rationale for performing a randomized, controlled trial (RCT) of cannabis-based medicine (CBM) in MS-related neuropathic pain is based on encouraging results using cannabinoid receptor agonists in relieving symptoms of experimental allergic encephalomyelitis⁷ and preliminary studies demonstrating modest positive effects of a synthetic cannabinoid analogue on neuropathic pain of mixed etiologies and of whole plant-derived CBM on neurogenic symptoms, including pain, in patients with MS.^{8,9} A systematic review of trials of cannabinoids in pain management concluded that cannabinoids may relieve neuropathic pain, but some authors have questioned the appropriateness of trials of cannabinoids using oral

Additional material related to this article can be found on the *Neurology* Web site. Go to www.neurology.org and scroll down the Table of Contents for the September 27 issue to find the link for this article.

From the Walton Centre for Neurology and Neurosurgery (Drs. Rog and Young), Liverpool, University of Liverpool (Drs. Rog, Nurmikko, and Young); Pain Research Institute (Dr. Nurmikko), Liverpool; Medical Statistics Unit (Dr. Friede), Lancaster University, Lancaster, United Kingdom.

Disclosure: David J. Rog, BMBS, Carolyn A. Young, MD, and Turo J. Nurmikko, PhD, contributed to the conception and design of this study and the drafting and revision of the paper. Drs. Rog and Young participated in the acquisition of trial data. Dr. Friede independently analyzed the study data and contributed to the drafting and revision of the paper. Dr. Rog has accepted travel and accommodation expenses from GW Pharma to attend an Investigator’s Meeting (less than \$10,000) and his salary was paid from a research fund to which GW Pharma contributed (in excess of \$10,000). Dr. Friede has no conflicts of interest; he is currently employed by Novartis Pharma, Basle, Switzerland. Drs. Young and Nurmikko have both received funding for research (in excess of \$10,000) from GW Pharma and Dr. Nurmikko has also received an honorarium (less than \$10,000) for speaking from GW Pharma.

GW Pharmaceuticals sponsored the trial, contributed to study design, provided trial medication and matching placebo and collected the data. GW Pharma Ltd. has contracted data handling and analysis to a contract research organization. The authors have received full access to the data and conducted an independent analysis. GW and Bayer Pharmaceuticals have had the opportunity to review the manuscript of the paper, but decision to publish rests with the authors.

Received January 15, 2005. Accepted in final form June 9, 2005.

Address correspondence and reprints to Dr. David J. Rog, Clinical Trials Unit, Walton Centre for Neurology and Neurosurgery, Liverpool, L9 7LJ, UK; e-mail: djrdjr@doctors.org.uk

administration due to the variability in their gastrointestinal absorption and crossover designs because of their long half-lives.^{10,11}

This study was designed to evaluate the effect of oromucosal CBM in central pain associated with MS. CBM is derived from cannabis plant chemovars, developed to produce high and reproducible yields of specified cannabinoids and formulated to produce a CBM. Oromucosal administration is efficient and convenient in achieving accurate self-titration to overcome the wide variability of interindividual response known to occur with cannabis and cannabinoids. The study preparation contained a mixture of two principal ingredients of cannabis (delta-9-tetrahydrocannabinol [THC] and cannabidiol [CBD]) in approximately a 1:1 ratio, with small amounts (<10%) of other cannabis-based compounds, delivered via an oromucosal spray. We sought to compare the efficacy, safety, and tolerability of CBM THC: CBD with placebo in relieving central neuropathic pain in patients with MS.

Methods. Adult patients with central neuropathic pain syndromes due to MS were invited to participate in this 5-week, four-visit, randomized, double-blind, placebo-controlled, parallel-group study conducted at the Walton Centre Clinical Trials Unit, Liverpool, U.K. Patients were identified predominantly from a previous study validating the Neuropathic Pain Scale¹² (NPS) in MS central pain¹³ and also from the regional MS clinic or by specialist referral. After written informed consent, eligible patients with MS diagnosed at least 6 months previously (Poser criteria¹⁴) were included. Central pain for which a nociceptive cause appeared unlikely was required to be of at least 3 months' duration and expected to remain otherwise stable during the study. As there is no gold standard for central pain, the diagnosis was made based on pain description and clinical examination that had to be compatible with a central mechanism and by exclusion.² Patients with dysesthetic pain perceived as an unpleasant abnormal sensation spontaneously occurring or evoked and often described using terms such as burning, aching, pricking, stabbing, and squeezing,² which is the most common form of chronic neuropathic pain associated with MS, were included as were those with painful tonic spasms. Those with chronic visceral pain, headache, spasticity-associated aching pain, secondary entrapment syndromes, or acute MS-related pains, e.g., optic neuritis or positive Lhermitte sign alone, were not included. Patients with dysesthetic pain described it predominantly in their legs and feet. Patients were excluded if their sensations were not subjectively deemed painful or if they had spasticity or painless spasms alone or another noncentral pain mechanism was considered more likely, e.g., musculoskeletal pain from postural changes or peripheral neuropathic pain from nerve entrapment. Patients taking amitriptyline or other tricyclic antidepressants were required to reduce to or maintain a maximum dose of 75 mg/day. A stable neuropathic pain medication regimen was maintained during the 2 weeks immediately before screening and throughout the study. Changes in medications or procedures expected to affect central MS pain were prohibited.

No cannabinoid use (cannabis, Marinol, or Nabilone) at least 7 days before screening or during the study was permitted. Patients consented to their details being notified to the British Home Office and agreed not to travel outside the United Kingdom or donate blood during the study.

Patients were ineligible if they had a history of major psychiatric disorder other than depression associated with their underlying condition; severe concomitant illness, seizures, history or suspicion of substance abuse; concomitant severe nonneuropathic pain or the presence of illness such as diabetes mellitus that could cause peripheral neuropathic pain; or scheduled procedures requiring general anesthesia during the study. Patients were also excluded if they were pregnant, lactating, taking levodopa therapy

within 7 days of study entry or had known or suspected hypersensitivity to cannabinoids.

The Local Research Ethics Committee approved the study and stipulated that patients should not drive during the study. Participants underwent assessment including calculation of Expanded Disability Status Scale¹⁵ (EDSS) score. Patients localized their pains using a body map. A pain history and bedside examination was undertaken to establish whether the pain or pains were likely to be of central origin, based on their location, quality or qualities, and associated sensory abnormalities such as hypoesthesia, allodynia, and hyperpathia. The patients' most troublesome central neuropathic pain was thus identified, and they then estimated at what time of day this was expected to be at its maximum severity. An 11-point numerical rating scale (NRS-11) (in which 0 = no pain and 10 = worst possible pain) was completed daily for the identified pain at the identified time for the 7- to 10-day baseline screening period and throughout the study. A daily NRS-11 scale recording sleep disturbance due to neuropathic pain rating (in which 0 = did not disrupt sleep and 10 = completely disrupts unable to sleep due to pain) was also completed. The NPS was completed at the same time as the pain NRS-11 for three consecutive days in both the run-in week and the final week of treatment.

The following items were examined before first dosing and at study completion or withdrawal: cognitive function (Brief Repeatable Battery of Neuropsychological Tests¹⁶), mood (Hospital Anxiety and Depression Scale¹⁷ [HADS]), and MS-related disability (Guy's Neurological Disability Scale¹⁸). At the end of the study, a Patient's Global Impression of Change¹⁹ (PGIC), a 7-point rating scale of a patient's overall change in status since commencing study medication, was applied.

Patients were randomized using a predetermined randomization code drawn up by a statistician who remained unknown to study personnel throughout the duration of the trial. Treatment allocation was made using randomized permuted blocks of four (two active drug, two placebo), with treatments sequentially assigned to either a whole-plant CBM (CBM = GW 1000-02, Sativex) containing THC: CBD delivered via oromucosal spray or placebo. Each spray delivered 2.7 mg of THC and 2.5 mg of CBD or placebo. Placebo was designed to match the appearance, smell, and taste of the active formulation but contained no active components, in ethanol:propylene glycol (50:50) excipient. To facilitate blinding, patients completed pain and sleep assessments at home, the physician examined patients, gave dosing advice, and assessed them for adverse events (AEs); trials nurses completed all other secondary outcome assessments; and a trials pharmacist dispensed the study medication. The identity of study medication assigned to patients, to which all study personnel remained blinded, was contained in individually sealed envelopes retained in the hospital 24-hour pharmacy and with the sponsor's Pharmacovigilance Department.

Sample size calculation. No large-scale, RCTs of MS central pain treatments existed to provide data for power calculations. From peripheral neuropathic pain studies of gabapentin,^{19,20} the SD for the change from baseline in the NRS-11 pain score was 2.1. For a difference of 1.75 on the NRS between the two treatment groups and a significance level of 5% (two sided), a sample size of 54 patients ensures a power of 85% in a balanced design. Assuming withdrawals or serious protocol violations of around 15%, approximately 64 patients were to be randomized (32 patients in each treatment group).

Study timetable and dosing. On the first day of treatment, up to four sprays were delivered in 2 hours and any signs of intoxication observed over 4 hours by the investigator and recorded by the patient on a 100-mm visual analogue scale (VAS) (0 = no intoxication and 100 = extreme intoxication). If the patient scored >25 mm on a predose VAS or the investigator had concerns, a dose could be omitted. Patients who satisfactorily completed initial dosing were given written instructions to begin home dose titration the following day. No specific target dose was set, and the patients were advised to increase the number of sprays stepwise on consecutive days up to 48 sprays (THC 129.6 mg: CBD 120 mg) in 24 hours. For safety reasons, the patients were advised to take no more than eight sprays (THC 21.6 mg: CBD 20 mg) within any 3-hour interval and refrain from up-titrating the daily dose by more than 50% from the previous day. If intoxication was experienced, patients were advised to reduce or omit a dose. If a maxi-

mum tolerated dose was thus established, it was only exceeded with caution.

During telephone follow-up, patients were advised to optimize dosing when suboptimal benefit had been achieved. Those patients who satisfactorily completed the trial were offered the opportunity to participate in an open-label extension study, which will be reported separately.

Data analysis. The intention-to-treat (ITT) population was used for all efficacy analyses and was defined as all patients who entered the study, were randomized, received at least one dose of study medication, and had on-treatment efficacy data. For all efficacy scores including pain NRS-11 as the primary endpoint, the change in scores from baseline to end of treatment (completion or withdrawal) was compared between treatment groups using analysis of covariance with the baseline score as covariate. For the NRS-11 scales, the mean score of the 7 days before the first dose was given served as baseline and the mean score of the last 7 (3 in the event of withdrawal) days before the final intake of test medication was used as final score. For the NPS, the average of the three replications in the run-in week served as the baseline score and in the final week of treatment as the final score. The PGIC was analyzed by comparing the proportions of patients rating themselves as “much” or “very much improved” using Fisher’s exact test. Additionally, the PGIC in the two treatment groups were compared using the cumulative logit model with treatment group as the only independent variable. The heart rates during the first dosing were modeled by a linear mixed model with fixed effects for treatment group means and slopes and individual patient random effects for means and slopes. For all binary variables apart from the dichotomized PGIC, we used χ^2 tests. All CIs for proportions or differences of proportions are approximate CIs. No adjustments for multiple testing were carried out. All analyses were performed using SAS version 8.2.

Results. Study population. Recruitment from the regional MS clinic and referrals from consultant neurologists and pain specialists took place between March and July 2002, and patients attended the Trials Unit on four occasions over 5 weeks. Eighty-five patients were screened, of whom 66 were randomized (fig 1), 34 to CBM and 32 to placebo; 64 patients (96.9%) completed the study. Two women patients withdrew, both on CBM. One developed an AE of agitation with tachycardia and hypertension after four sprays, which settled with conservative management within 3 hours. She declined further study medication and withdrew 7 days later without completing further scores. The second patient developed paranoid ideation and was withdrawn from study medication at the investigator’s discretion in the second treatment week but subsequently completed all study diaries and assessments. Two patients violated the protocol, one patient’s concomitant pain medication changed in the run in period, and another patient commenced interferon treatment 3 days after commencing the study. Both patients were in the active treatment group and were included in the ITT analysis.

Of the 66 patients randomized, nine had primary progressive, 33 secondary progressive, 23 relapsing remitting and one benign MS. The treatment groups were well balanced in terms of gender, age, duration of MS since diagnosis, and baseline NRS-11 pain score (table 1). At baseline, the NPS items Intense, Unpleasant, and Deep were experienced by more than 80% of patients with mean severities of greater than four of ten. Conversely, less than 25% of patients experienced Cold and Itchy components with a similar magnitude and about 45% of patients did not experience these pain qualities at all.

Forty-three patients (65%) required support to walk or were wheelchair bound. Patients were taking a mean of about two other medications for pain, spasms, or spastic-




Figure 1. Profile of patients at each stage of the study.

ity. Forty-seven percent of patients had previous experience of using cannabis medicinally and 16.7% recreationally. Only four patients randomized to CBM and eight to placebo had taken cannabis within 3 months of study entry. The proportion of patients with any previous exposure to cannabis was not different between CBM and placebo (CBM 15/34, placebo 21/32; CBM-placebo -0.22 , 95% CI: -0.45 to 0.02 , $p = 0.08$). The mean number of daily sprays taken in week 4 was 9.6 of CBM ($n = 32$) (range 2 to 25, SD = 6.1), equivalent to 25.9 mg THC:24 mg CBD and 19.1 of placebo ($n = 31$) (range 1 to 47, SD = 12.9) (CBM-placebo -9.5 , 95% CI: -14.6 to -4.4 , $p = 0.0004$).

Efficacy measures. NRS-11 and NPS total pain scores. Significant mean reductions favoring CBM were found for the primary outcome NRS-11 of pain and the secondary outcome NPS (table 2 and figures 2 and 3). Of the total 65 patients included in the ITT analysis, 59 (89%) had dysesthetic pain and seven (11%) had painful spasms. Post hoc analysis demonstrated that the seven patients with painful spasms had higher baseline NRS-11 pain intensities than the patients with dysesthetic pain (dysesthetic pain 6.3 [SE = 1.6]; painful spasms 7.3 [SE = 1.5]; difference in means = 1.3, 95% CI: 0.1 to 2.6, $p = 0.04$) and that the changes from baseline to week 4 tended to be greater in

Table 1 Baseline demographic details

	All patients	CBM	Placebo
Randomized	66	34	32
M:F	14:52	6:28	8:24
Mean age, y (range, SD)	49.2 (26.9–71.4, 8.3)	50.3 (37.6–63.9, 6.7)	48.1 (26.9–71.4, 9.7)
Mean duration of MS since diagnosis, y, (range, SD)	11.6 (1.6–36, 7.7)	10.4 (1.0–28.0, 7.3)	12.8 (2.0–36, 8.1)
Mean EDSS at study entry, (range, SD)	5.9 (2.0–8.5, ± 1.3)	6.0 (3.0–8.0, ± 1.1)	5.8 (2.0–8.5, ± 1.5)
0–3.5 unlimited	3	1	2
4.0–5.5 limited	20	8	12
6.0–6.5 walking aids	26	17	9
7.0–9.5 wheelchair	17	8	9
No. of concomitant analgesics, mean, (range, SD)	1.8 (0–5, 1.2)	1.8 (0–5, 1.2)	1.8 (0–4, 1.3)
Acetaminophen	8	4	4
Tricyclic antidepressant	18	13	5
Anesthetic	1	1	0
Anticonvulsant	13	8	5
Benzodiazepine	3	2	1
Evening primrose oil	1	0	1
Combination opioid	22	9	13
Opioid	5	2	3
Strong opioid	3	3	0
NSAID (oral)	17	5	12
NSAID (topical)	2	0	2
Skeletal muscle relaxant	25	14	11
Total	118	61	57
Previous medicinal cannabis use	31 (47%)	14 (41.2%)	17 (53.1%)
Previous recreational cannabis use	11 (16.7%)	3 (8.8%)	8 (25%)
Location of pain			
Upper limb unilateral	6	5	1
Upper limb bilateral	4	2	2
Lower limb unilateral	11	7	4
Lower limb bilateral	36	17	19
Ipsilateral upper/lower limbs	2	0	2
Lower limb spasms	7	3	4
Mean baseline NRS-11 pain score (range, SD)	6.5 (3–10, 1.6)	6.5 (3–10, 1.6)	6.4 (4–10, 1.7)

CBM = cannabis-based medicine; EDSS = Expanded Disability Status Scale; NSAID = nonsteroidal antiinflammatory drug; NRS-11 = 11-point numerical rating scale.

patients with painful spasms. In the patients with dysesthetic pain, the mean changes were -2.4 (SD = 1.5, n = 30) for CBM and -1.3 (SD = 1.7, n = 28) for placebo, whereas these changes were -5.7 (SD = 3.5, n = 3) and -2.1 (SD = 1.6, n = 4) in the patients with spasm. In an analysis including only the patients with dysesthetic pain, the NRS-11 pain treatment effect was 1.1 (SE = 0.4, $p = 0.012$). An interaction between treatment and type of pain was not found on a 5% level ($p = 0.07$).

Post hoc analysis of individual NPS items demonstrated treatment effects for all 10 items in favor of CBM that reach significance for Intense (treatment effect estimate -1.31 , 95% CI: -2.21 to -0.40 , $p = 0.0054$), Dull (treatment effect estimate -1.04 , 95% CI: -2.05 to -0.03 , $p =$

0.0433) and Sensitive (treatment effect estimate -1.01 , 95% CI: -2.02 to -0.01 , $p = 0.0484$).

Pain-related sleep disturbance. The reductions in pain were reflected in similar reductions in mean daily pain-related sleep disturbance with a mean treatment difference favoring CBM (table 2, figure 4).

PGIC. The proportion of patients rating themselves as “much” or “very much improved” in the CBM group (9/34) was not greater than those receiving placebo (4/32) (treatment difference 14% points, 95% CI: -4.8 to 32.7, $p = 0.218$). No patient felt “much worse” or “very much worse” (see table E-1 on the *Neurology* Web site at www.neurology.org). On the 7-point PGIC, those treated with CBM were 3.9 times more likely to rate themselves in any

Table 2 Changes in pain and sleep by treatment (CBM = 33, placebo = 32)

	Mean NRS-11 pain (95% CI)		Mean NPS total (95% CI)		Mean NRS-11 sleep disturbance (95% CI)	
	CBM	Placebo	CBM	Placebo	CBM	Placebo
Baseline week	6.58 (6.00–7.15)	6.37 (5.77–6.97)	46.90 (41.74–52.07)	45.79 (40.23–51.36)	5.26 (4.35–6.18)	4.47 (3.52–5.42)
Final treatment week	3.85 (3.13–4.58)	4.96 (4.19–5.72)	31.90 (26.56–37.25)	37.73 (31.40–44.06)	2.69 (1.99–3.39)	3.64 (2.73–4.55)
Mean treatment difference CBM – placebo (95% CI)	–1.25 (–2.11 to –0.39) <i>p</i> = 0.005		–6.58 (–12.97 to –0.19) <i>p</i> = 0.044		–1.39 (–2.27 to –0.50) <i>p</i> = 0.003	

The mean treatment differences are adjusted for baseline measurements.

CBM = cannabis-based medicine; NRS-11 = 11-point numerical rating scale; NPS = neuropathic pain scale.

improved category than those receiving placebo (95% CI: 1.51 to 10.09, *p* = 0.005).

AEs. Thirty patients (88.2%) on CBM developed at least one AE, compared with 22 patients (68.8%) on placebo (CBM-placebo 0.19, 95% CI: 0.00 to 0.39, *p* = 0.053). Common AEs are summarized in table 3; in addition, confusion, crying, low mood, disorientation, paranoia, hallucination, and logorrhea all occurred once in the CBM group. Fifty-three percent of the patients in the CBM group experienced dizziness at least once compared to 16% in the placebo group (CBM-placebo 0.37, 95% CI: 0.16 to 0.58, *p* = 0.002). Some of the psychiatric AEs occurred in the same patient. No serious AEs, i.e., fatal, life-threatening, or resulting in persistent or major disability/incapacity or prolonging hospitalization, occurred. However, two women patients in the CBM arm experienced AEs severe enough to warrant trial withdrawal (see “Study Population” section).

No significant changes were seen in either group in blood pressure, weight, temperature, hematology, or blood chemistry. During the first dosing, there was an increase in mean heart rate in 1 hour in the cannabis-based medicine group by 3.2 beats per minute (95% CI: 2.3 to 4.1) compared with a mean of 1.6 beats per minute (95% CI: 0.8 to 2.5) in the placebo group, *p* = 0.016.




Figure 2. Mean 11-point numerical rating scale (NRS-11) pain scores (\pm SEM) for the cannabis-based medicine (CBM) (*n* = 33) and placebo group (*n* = 32). Week 0 refers to the run-in week. The patients were on test medication in weeks 1 to 4.

Neuropsychological outcomes. No significant differences between mean changes on each treatment were found in the 10/36 Spatial Recall Test, Symbol Digit Modalities Test, Paced Auditory Serial Addition Test, or Word Generation List between treatment groups on neuropsychological testing. In the long-term component of the Selective Reminding Test (SRT), a difference was found because of a mean improvement in the placebo group (*n* = 32) of 5.7 (95% CI: –19 to 26) not matched in the CBM group (*n* = 33) of –0.9 (95% CI: –20 to 23) mean treatment difference –6.95 (95% CI: –12.12 to –1.77), *p* = 0.009 (see table E-2).

Other secondary outcomes. No differences between mean changes on each treatment were found between treatment groups in the other secondary measures of HADS anxiety and depression and Guy’s Neurological Disability Scale (see table E-3).

Discussion. This randomized, placebo-controlled trial demonstrates a beneficial effect of CBM both in the relief of central pain associated with MS and pain-related sleep disturbance. Although our study’s inclusion criteria allowed for any type of MS-related




Figure 3. Mean neuropathic pain scale (NPS) scores (\pm standard error of mean) for the cannabis-based medicine (CBM) (*n* = 33) and placebo group (*n* = 32) at baseline (Visit 1) and end of treatment (Withdrawal/Completion).




Figure 4. Mean sleep disturbance 11-point numerical rating scale (NRS-11) scores (\pm SEM) for the cannabis-based medicine (CBM) ($n = 33$) and placebo group ($n = 32$). Week 0 refers to the run-in week. The patients were on test medication in weeks 1 to 4.

central pain of greater than 3 months' duration, the predominance of dysesthetic extremity pain in this study (59 patients [89%]) is in agreement with previous series.^{2,5} The definition of and conditions encompassing "neuropathic" pain remain controversial.²² No universally accepted validated clinical diagnostic criteria for neuropathic pain exist,²² and assessment of patients based on clinical examination and bedside tests to decide what is and what is not neuropathic is difficult, even for experts.²³

Some authors view spasm-related pain in MS as being neuropathic,⁵ whereas others do not.²¹ A crossover trial of dronabinol in MS central pain specifically excluded patients with spasm-related pain.²¹ Painful spasms in MS feature sudden-onset, either unilateral or bilateral, dystonic posturing with a stereotyped pattern in the same patient. They are thought to be caused by "a transversely spreading ephaptic activation of axons within a partially demyelinated lesion."^{24,25} No study to date has linked painful spasms to dysfunction in either the motor or somatosensory system exclusively, and whether there is any advantage in separating the two for therapeutic purposes is uncertain. Although patients with MS and painful spasm must have a CNS lesion, the key question is whether the pain is generated primarily in the spasmodic muscles or the CNS. In this study, patients with painful spasms responded similarly to those with predominantly dysesthetic pain, suggesting that dichotomizing patients based on putative differences in central mechanisms of the two groups may be superfluous.

Patients in our study were taking, on average, two other medications, with limited efficacy given baseline NRS-11 pain scores of 6.5. Therefore, as adjunctive analgesic treatment, CBM had a significant treatment effect of -1.25 , in the NRS-11, in excess of the -0.6 achieved by oral dronabinol in an MS study in which concomitant analgesia was restricted to

Table 3 Summary of common adverse events during parallel group treatment

Adverse event and category	No. experiencing on CBM, $n = 34$	No. experiencing on placebo, $n = 32$
Nervous system		
Dizziness	18	5
Somnolence	3	0
Disturbance in attention	2	0
Headache	1	3
Psychiatric		
Dissociation	3	0
Euphoria	2	0
Gastrointestinal		
Dry mouth	4	0
Nausea	3	2
Diarrhea	2	0
Glossodynia	1	3
Mouth ulceration	1	0
Vomiting	1	0
Dyspepsia	0	1
Oral pain	0	3
General and administration site conditions		
Falls	3	2
Weakness	3	0
Fatigue	2	2
Feeling abnormal	1	0
Feeling drunk	1	1
Thirst	1	0
Application site burning	0	1
Chest discomfort	0	1
Respiratory		
Pharyngitis	2	1
Hoarseness	1	0
Throat irritation	1	0
Dyspnea	0	1

paracetamol²¹ and comparable to treatment effects of approximately 0.9 and 1.25 to 1.45 in RCTs of peripheral neuropathic pain using tramadol and pregabalin.^{26,27} The treatment difference for the NRS-11 did not reach that for which the study was powered, although this calculation was based on peripheral neuropathic pain studies.^{19,20} A meta-analysis of more than 2,700 patients with various painful conditions suggested approximately a 30% or 2-point NRS-11 score reduction in pain as being clinically significant²⁸ but notably did not include patients with central neuropathic pain, in which "relatively small decreases in pain intensity are often highly valued by the patients."²²

In our study, the numbers needed to treat²⁹ to achieve a 50% reduction in central pain in at least one patient was 3.7 (95% CI: 2.2 to 13.0), similar to that obtained in the dronabinol trial of 3.5 (95% CI: 1.9 to 24.8).²¹ Numbers needed to harm²⁹ (NNH) is calculated as 1/risk difference, and for the probabilities of at least one AE, this is $1/0.19 = 5.13$. Specifically, for CBM to cause dizziness, the NNH was $1/0.37 = 2.68$. Current options for treating central pain conditions remain limited and are based mostly on the use of CNS drugs with known problems of tolerability.^{30,31} CBM was well tolerated overall, despite a population including 25 of 34 patients (73.5%) in the treatment group requiring some walking aid and eight (24%) being wheelchair bound.

A systematic review identified that, until 2001, RCTs of cannabinoids were largely confined to single-dose trials.¹⁰ In this trial, patients could titrate to a maximum of THC 130 mg:CBD 120 mg. The mean dose achieved of 25.9 mg THC, and particularly 24 mg CBD, is in excess of that used in other cannabinoid RCTs.^{21,32,33} CBD is thought to modulate the effects of THC and also to have analgesic properties of its own. These factors may contribute to the positive outcomes in this trial. To place these reductions in patient's pain in context, a quality-of-life instrument would have been beneficial, however, with a relatively short 3-week fixed treatment period. This was omitted from our study; however, an odds ratio of 3.9 favoring an improved global impression of change with CBM, without a corresponding significant change in mood, suggests that patients felt a benefit from reduction in pain, sleep improvement, or both and contrasts with a previous RCT using orally administered THC and whole-plant cannabis extract, which significantly reduced PGIC.³² The Cannabinoids in Multiple Sclerosis (CAMS) trial using orally administered cannabinoid capsule formulations identified no objective change in Ashworth scores but did note subjective improvements in pain and sleep, which concurs with our results, as well as in spasms and spasticity.³³

In our study, the NPS 10-item total responsiveness also shows a significant treatment difference favoring CBM of -6.58 on a 100-point scale, demonstrating convergence with the traditionally accepted NRS-11 outcome. Post hoc analysis demonstrated significant treatment effects favoring CBM in the Intense, Dull, and Sensitive NPS items, suggesting that further studies should examine whether more sophisticated methods of analyzing the NPS are required.

Although unusual in neuropathic pain trials, some RCTs involving cannabinoids have included a question to formally assess the degree of blinding and demonstrated an element of unblinding in patients receiving cannabinoids.^{32,33} Our study did not include a blinding question. However, despite a number of our patients having previous exposure to cannabis, our placebo group experienced both a large reduction

in pain and number of AEs, suggesting a degree of blinding was preserved.

CBM does not appear to have significant effects on MS-related disability, mood, or on four of the five neuropsychological outcomes measured. No corrections for multiple comparisons were applied to secondary outcomes. The significant treatment effect-favoring placebo in the long-term storage component of the SRT, perhaps reflects a learning effect not matched in the CBM group. Analyses of the consistent long-term retrieval score and delayed recall at 11 minutes were not defined a priori for analysis in our study. The neuropsychological outcomes of chronic (10.2 to 24 years) recreational marijuana users and general population controls have been compared.³⁴ On the Rey Auditory Verbal Learning Test, a significantly less steep learning curve and generally recall of fewer words were observed in long-term (mean 24 years) users of cannabis than in short-term (mean 10.2 years) users or controls. Long-term users also recalled fewer words than short-term users or controls. The preliminary results of the psychological substudy of the CAMS trial found a significant reduction in the Californian Adult Verbal Learning Test in those receiving cannabis extracts compared with placebo.³⁵ These results require further analysis and incorporation of psychological outcomes in future cannabinoid trials.

Acknowledgment

The authors thank all patients who took part in the study. They acknowledge the assistance of the staff of the Clinical Trials Unit at the Walton Centre for Neurology and Neurosurgery who helped in the conduct of the study and application of many of the secondary outcome measures, especially Lynne Owen, Dot Marshall, Dave Watling, Lynne Pickering, C. Saminaden, Linda Moss, and Ann Dennis (pharmacist).

References

1. Mersky H, Bogduk N. Classification of chronic pain. Seattle: IASP Press, 1994.
2. Bivov J. Central pain. In: Wall, PD, Melzack R, eds. Textbook of pain, 4th ed. Hong Kong: Harcourt, 1999:879-914.
3. Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. *Acta Neurol Scand* 1991;84:197-200.
4. Thompson AJ. Symptomatic treatment in multiple sclerosis. *Curr Opin Neurol* 1998;11:305-309.
5. Bonica JJ. Introduction: semantic, epidemiologic, and educational issues. In: Casey, KL, eds. Pain and central nervous system disease: the central pain syndromes. New York: Raven Press, 1991:21.
6. Pertwee RG. Cannabinoid receptors and pain. *Prog Neurobiol* 2001;63:569-611.
7. Lyman WD, Sonett JR, Brosnan CF. Delta 9 tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. *J Neuroimmunol* 1989;23:73-81.
8. Karst M, Salim K, Burstein CI, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled trial. *JAMA* 2003;290:1757-1762.
9. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. *Clin Rehabil* 2003;17:21-29.
10. Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ* 2001;323:13-16.
11. Pertwee RG. Prescribing cannabinoids for multiple sclerosis: current issues. *CNS Drugs* 1999;11:327-334.
12. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. *Neurology* 1997;48:332-338.
13. Rog DJ, Young CA. Validation and reliability of the Neuropathic Pain Scale in multiple sclerosis. *Mult Scler* 2001;7:S111. Abstract.

14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. *Ann Neurol* 1983; 13:227–231.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale. *Neurology* 1983;33:1444–1452.
16. Rao SM. Cognitive Function Study Group. National Multiple Sclerosis Society. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society, 1990.
17. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. *Acta Psychiatr Scand* 1983;67:361–370.
18. Sharrack B, Hughes RAC. Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. *Mult Scler* 1999;5:223–233.
19. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. *JAMA* 1998; 280:1837–1842.
20. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. *JAMA* 1998;280:1831–1836.
21. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 2004;329:253–258.
22. Attal N, Bouhassira D. Can pain be more or less neuropathic? *Pain* 2004;110:510–511.
23. Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. *Pain* 2004;110:461–469.
24. Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. Anatomic correlates of painful tonic spasms in multiple sclerosis. *Mov Disord* 1999;14:331–335.
25. Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. *Brain* 1975;98:189–202.
26. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, placebo-controlled trial. *Pain* 2003;104:323–331.
27. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy. A randomized controlled trial. *Neurology* 2004;63:2104–2110.
28. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 2001;94:149–158.
29. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. *Pain* 1999;83:389–400.
30. Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. *Mult Scler* 1997;3:250–253.
31. Ramsarasing G, Zwanikken C, De Keyser J. Drug points: worsening of symptoms of multiple sclerosis associated with carbamazepine. *BMJ* 2000;320:1113.
32. Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. *Neurology* 2002;58: 1404–1437.
33. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* 2003; 362:1517–1526.
34. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. *JAMA* 2002;287: 1123–1131.
35. Langdon DW, Thompson AJ, Johnson KP, et al. The psychological effects of cannabis in MS: impact on cognition, pain, mood and fatigue. *Mult Scler ECTRIMS* 2003;9:S27. Abstract.

Corrections

Posterior thalamic hemorrhage induces “pusher syndrome”

In the article “Posterior thalamic hemorrhage induces ‘pusher’” syndrome (*Neurology* 2005;64:1014–1019) by Karnath et al., the observed overall percentage of patients with pushing behavior following a thalamic stroke has been erroneously stated as 28%. The correct percentage is 35%, which should have been stated on page 1016, left column, paragraph 1 of Results and on the same page, right column, paragraph 1 of Discussion. The authors apologize for this error.

Familial hemiplegic migraine: More than just a headache

In the editorial “Familial hemiplegic migraine: More than just a headache” (*Neurology* 2005;64:592–593) by Benatar and Ford, Dr. Ford’s middle initial was incorrect. The author’s correct name is Corey C. Ford.

Neurology[®]

Corrections

Neurology 2005;65;819-819-a
DOI 10.1212/WNL.65.6.819-a

This information is current as of September 26, 2005

Updated Information & Services

including high resolution figures, can be found at:
<http://n.neurology.org/content/65/6/819.2.full>

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints

Information about ordering reprints can be found online:
<http://n.neurology.org/subscribers/advertise>

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

